All News
Last abstract of #ACR23 was #ACRBest
Plasma cfDNA signatures (synovial mapped) to identify RA vs OA, other inflamm arthritis
Great performance, even with seroneg RA
A blood test to:
diagnose
?phenotype
?identify best b/tsDMARD
Could be massive
Peter Taylor ABST2586 @RheumNow https://t.co/tJX2jXV0Oe
David Liew drdavidliew ( View Tweet)
#ACRbest Yrin Preview @ACRheum
J Bathon
Take home
Symptomatic #Rx of ACPA+ people WITH #DMARD is too late to alter risk of #RA when drug is d/c
AI to read joint erosions on X-ray May be ‘too little too late’
#Steroids in #RA increase #MACE even after d/c
#ACR23 @RheumNow
Janet Pope ( View Tweet)
Identifying GCA diagnosis and disease activity through proteomics from plasma:
diagnosis looks good
disease activity looks harder
(Much like a lot of things in GCA, really)
Exciting work @MayoClinic @MdWarrington @jsung0906 #ACR23 ABST2601 @RheumNow https://t.co/SwxN58LieB
David Liew drdavidliew ( View Tweet)
#ACR23 Yr in Preview
J Bathon
Shared decision making w tradeoffs showed sex differences for concerns & preferences in #RA present
dependent on how you ask the questions
Unmet needs (I think 🤔)
biomarkers of flare for #inflammatory #arthritis
Rx select’n/retention
@RheumNow
Janet Pope ( View Tweet)
Is MSOT the New Ultrasound?
Dr. Aurelie Najm reports on oral abstract 0750 presented at #ACR23
https://t.co/okbGHTR0i3 https://t.co/9zkHPiFl74
Dr. John Cush RheumNow ( View Tweet)
Watch: Assessment and Treatment of Cardiovascular Risks in Rheumatoid Arthritis
Dr. Antoni Chan discusses abstract 0387 and abstract 0391 presented at #ACR23
https://t.co/avnarOGZui https://t.co/4CeAumv31b
Dr. John Cush RheumNow ( View Tweet)
Greigert et al. IL17 in GCA. Increases vascular inflammation. Synergistic effect on myofibroblasts with IFN-γ - increases IL-1B, IL-6, GM-CSF, CCL20 (recruits T cells), CCL2 (recruits monocytes), VEGF (neoangiogenic). Abstr#2599 #ACR23 @RheumNow https://t.co/p4GumZStAZ https://t.co/zZv0TF4fmn
Richard Conway ( View Tweet)
Telitacicept a recombinant fusion protein targeting, neutralizing BLyS and APRIL, phase 3 study in RA MTX-IR at 24 wk, ACR20 (60% vs 27% PBO), ACR50 (21% vs 6% PBO), reduced DAS28-ESR, no radiographic progression, Wang L Abst#L20 #ACR23 #ACRBest @RheumNow https://t.co/nuvizqQZsR https://t.co/PRtlea3AqU
Dr. Antoni Chan ( View Tweet)
#ACR23 Abstr#2587 Can we agree on how to measure frailty in #SLE? A cohort study: moderate agreement at best among SLICC-FI, SPPB, FRAIL=>2 & PROMIS PF=<40. SLICC-FI was robust predictor of all outcomes except for cognitive impairment. FRAIL & PROMIS not far behind @RheumNow https://t.co/qWjM4crPvg
Md Yuzaiful Md Yusof ( View Tweet)
A randomised clinical trial show improvements in clinical outcomes CDAI, VAS for both the ITIS diet and the Med diet. Baseline differences in the microbiome between responders and non-responders were seen. Sala Climent M, Abst#2124 #ACR23 @RheumNow https://t.co/tiyNcV7cmD https://t.co/EEP4zrwjXs
Dr. Antoni Chan ( View Tweet)
Abstract 2583 at #ACR23
👉Possible predictive model of at risk of RA patients with ACPA positivity based on baseline levels of peripheral blood lymphocyte sub-populations:
⭐️High % of B cell and low % of NK cells increase the probability of developing arthritis in ACPA + pts… https://t.co/3KEOI4eul0 https://t.co/irX6InWMbl
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Large French study on infection risk of PsA biologics
12k pts over 6 years
When compared to Humira, only Enbrel and Stelara had lower infection risk
Concurrent steroid use associated with increased infection 1.85HR
@RheumNow #ACR23 Abs#2566 https://t.co/Os1esuodfl
Robert B Chao, MD ( View Tweet)
Saliclick: minor salivary gland biopsy was a safe and rapid procedure for the diagnosis in Sjögren’s Syndrome without observed numbness occurring, focal lymphocytic sialadenitis in 20%, with a focus score >1 for 62%. Hugle T, Abst#2190 #ACR23 @RheumNow https://t.co/VYKdQw2YlC https://t.co/dWLWj2AdkI
Dr. Antoni Chan ( View Tweet)
Trajectory of FVC in Systemic sclerosis associated ILD in open label SENSCIS study
Decline in FVC over 52 weeks decreased by 57% on nintedanib
But am I also just seeing a study FVC decline even with nintedanib?
@RheumNow #ACR23 Abs#2594 https://t.co/3h4mhm0ceU
Robert B Chao, MD ( View Tweet)
A model for prediction of progression to RA
Factors asso w/ progression
-ACPAs
-High % B cells
-Low % NK cells
Only in ACPA+ individuals
Low ACPA titers, High % NK cells and Low B cells = 76% non progressors
@RheumNow #ACR23 ABST2583 https://t.co/vNIwyrOJtJ
Aurelie Najm ( View Tweet)
AR882 a novel and selective URAT1 inhibitor is a safe, efficacious sUA lowering, tophus resolution and with a 68% decrease in total urate crystal volume of the feet and ankles after AR882 75 mg once daily for 6 months. Keenan R, Abst#L15 #ACR23 @RheumNow https://t.co/gMCcSI1v9W https://t.co/lk3XQCaw0A
Dr. Antoni Chan ( View Tweet)
⭐️Further Assessment of a patient with rash c/w leukocytoclastic vasculitis:
👉History:
⏺️Timing, onset, progression?
⏺️Recent infectious for infectious symptoms?
⏺️Recent/new meds?
⏺️Hx of cancer?
👉Laboratory assessment for ALL:
⏺️CBC w/ diff
⏺️CMP (w/ interest in Cr,… https://t.co/tVqz6XDXt2 https://t.co/LqZpx5j0Bp
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
1st Large real world observational head to head study on tx of Systemic sclerosis - ILD
No difference in treatment effectiveness of FVC change between tocilizumab, rituximab, mycophenolate and cyclophosphamide!
@RheumNow #ACR23 Abs#2596
#ACRBest https://t.co/GaSnZSCcnZ
Robert B Chao, MD ( View Tweet)
Fecal transplant for treatment of GI complications of systemic sclerosis?
No change in those who received transplant...
Overall procedure safe
@RheumNow #ACR23 Abs#2597 https://t.co/TEdeGHuzpi
Robert B Chao, MD ( View Tweet)